- cafead Jun 14, 2024 at 12:02: PM
via Despite continuing to generate blockbuster sales numbers for companies like Eli Lilly and Novo Nordisk, data analytics and consulting company GlobalData predicts the GLP-1 drug class will still face some headwinds in the obesity market.
In a Thursday briefing, GlobalData revealed that GLP-1 receptor agonist sales pulled in $25 billion last year in seven major markets–the U.S., France, Spain, Germany, Italy, Japan, and the U.K.—and predicted they will reach a total of $111 billion by 2033. GlobalData’s latest estimates appeared to be a slight downward change from a May 2024 report that pegged sales reaching $125 billion in the combined type 2 diabetes and obesity markets.
article source
In a Thursday briefing, GlobalData revealed that GLP-1 receptor agonist sales pulled in $25 billion last year in seven major markets–the U.S., France, Spain, Germany, Italy, Japan, and the U.K.—and predicted they will reach a total of $111 billion by 2033. GlobalData’s latest estimates appeared to be a slight downward change from a May 2024 report that pegged sales reaching $125 billion in the combined type 2 diabetes and obesity markets.
article source